ALB and heart failure: The relationship between early human albumin treatment and 28-day mortality was still significant in other subgroups, including age < 75 or age ≥ 75, with or without heart failure, without renal failure, non-glucocorticoid use, SOFA ≤ 10, and mild or moderate hypoxemia.